Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib + PLD in platinum-resistant ovarian cancer
NCT03161132Phase 2Completed
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Dec 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC), sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: Progression-Free Survival at 6 months. Started Dec 2017; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03161132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161132.